aica ribonucleotide has been researched along with Retinoblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gragoudas, E; Kayama, M; Kolovou, PE; Ksander, BR; Miller, JW; Morizane, Y; Nicolaou, F; Theodoropoulou, S; Vavvas, DG | 1 |
| Brodowska, K; Gragoudas, ES; Kayama, M; Miller, JW; Morizane, Y; Theodoropoulou, S; Vavvas, DG | 1 |
2 other study(ies) available for aica ribonucleotide and Retinoblastoma
| Article | Year |
|---|---|
Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Hypoglycemic Agents; Phosphorylation; Retinoblastoma; Ribonucleotides; Signal Transduction | 2010 |
Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis.
Topics: Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Retinoblastoma; Ribonucleotides; S Phase | 2013 |